SureTrader Advertisement Advertisement
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator gotinearly, 1-eye-jack, ronrooster, sizzleweed, Kbro13
Search This Board:
Last Post: 10/9/2015 2:24:56 PM - Followers: 465 - Board type: Free - Posts Today: 0






Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328

Web site:


CIK 0001449447

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)

Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.



David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 Recent News!

June 1, 2015




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ENTB News: Current Report Filing (8-k) 10/02/2015 03:06:12 PM
ENTB News: Current Report Filing (8-k) 07/31/2015 03:24:13 PM
ENTB News: Quarterly Report (10-q) 07/09/2015 05:21:46 PM
ENTB News: Current Report Filing (8-k) 06/26/2015 06:15:40 AM
ENTB News: Current Report Filing (8-k) 05/22/2015 09:13:17 AM
#37380  Sticky Note Entest BioMedical's Zander Therapeutics Unit Files Patent Application gotinearly 08/11/15 09:52:49 AM
#37329  Sticky Note Recent News: Kbro13 08/07/15 03:17:10 PM
#37605   That's what can be expected when Koos puts JokersWild12 10/09/15 02:24:56 PM
#37604   This sucks not even a bone. oneflew12 10/09/15 02:17:49 PM
#37603   news in reality is no news just jhenmal 10/08/15 08:26:34 PM
#37602   What a FLOP. I've never seen a CEO JokersWild12 10/08/15 10:56:09 AM
#37601   This is what happens when things don't look Brakeman 10/06/15 10:21:24 AM
#37600   Prof81, I love the way you dream and ctvette2003 10/06/15 09:40:39 AM
#37599   Holy crap!!!! Wait till everyone hears what's going prof81 10/06/15 09:21:41 AM
#37598   Get out now and buy back in at Lockman 10/05/15 12:57:52 PM
#37597   Remember that when the R/S was completed, there bucks2pennies 10/03/15 04:15:36 PM
#37596   ENTB. "On September 28, 2015 Zander Therapeutics, bucks2pennies 10/02/15 04:04:35 PM
#37595   Thats a Great Story ! He haw, but Brakeman 10/02/15 12:28:35 PM
#37594   Bucks,good realistic summary.I agree with you that our ronrooster 10/02/15 12:22:43 PM
#37593   ENTB. A little forethought. This is bucks2pennies 10/02/15 11:39:23 AM
#37592   At least this week no PR's from the JokersWild12 10/02/15 10:16:57 AM
#37590   I didnt know until this group of Koos JokersWild12 10/01/15 11:26:28 AM
#37589   Crony is the correct spelling, and I agree.:( Brakeman 09/30/15 08:24:52 AM
#37588   Who are the cronies in this post? gotinearly 09/29/15 04:36:59 PM
#37586   Indeed! Brakeman 09/29/15 01:45:21 PM
#37585  Restored "KOOS the INCOMPETENT" is one of the "masters" angelicsatan666 09/29/15 07:19:13 AM
#37584   What is good for the Koos, is not sizzleweed 09/29/15 12:06:10 AM
#37583   interesting mirror trades gotinearly 09/28/15 04:27:23 PM
#37582   ENTB. Another year, another one and then bucks2pennies 09/28/15 02:41:48 PM
#37581   Bucks your expectation for this is not that JokersWild12 09/28/15 12:24:25 PM
#37580   Because of the REVERSE SPLIT, and the "estimated angelicsatan666 09/28/15 11:46:21 AM
#37579   ENTB trading is tight. Those that are on bucks2pennies 09/25/15 03:05:16 PM
#37578   Regen's progress = ENTB/Zander potential. ronrooster 09/25/15 01:20:07 PM
#37577   Go ENTB! Get up! Don't drop that right bucks2pennies 09/25/15 11:20:16 AM
#37576   wow .01 is support, better hold or Lockman 09/24/15 11:15:56 PM
#37575   So you got out at $0.08 when it Brakeman 09/24/15 04:55:47 PM
#37574   Your a pro like Koos $$$$ Brakeman 09/24/15 03:45:17 PM
#37573   i cant believe i was able to escape fuzzyforeigner 09/24/15 03:26:17 PM
#37572   At least he had the decency,honor and respect Brakeman 09/24/15 02:17:19 PM
#37571   ENTB. No Nans? So what? What? There bucks2pennies 09/24/15 01:23:42 PM
#37570   Looks like since the split Koos took about Brakeman 09/24/15 12:56:15 PM
#37569   At least Koos had the decency to inform ronrooster 09/24/15 12:46:38 PM
#37568   not to bash but agreed and well said jhenmal 09/24/15 12:13:57 PM
#37567   Koos cant complete a deal to save his JokersWild12 09/24/15 12:09:55 PM
#37566* jhenmal 09/24/15 12:05:04 PM
#37565 are spot on..appeared that the rs coupled JokersWild12 09/24/15 09:39:19 AM
#37564   ENTB. I am nervous though. I bucks2pennies 09/23/15 06:34:52 PM
#37563   Agreed! If they were diluting, things would NotARookie31 09/22/15 09:15:57 AM
#37562   THERE ARE NOT ENOUGH SHARES SOLD TO DILUTE ANYTHING! ronrooster 09/22/15 08:53:52 AM
#37561   ~ ENTB = Dilution, Dilutions, Dilution, R/S, Dilutions,..etc..etc!!..:-( 1-eye-jack 09/22/15 12:32:42 AM
#37560   ENTB is being 'groomed' for things to come, bucks2pennies 09/21/15 06:46:47 AM
#37559   Next week will be ENTB's turn to move ronrooster 09/18/15 03:24:10 PM
#37558   Regen BioPharma, Inc. Files Utility Patent Application on ronrooster 09/16/15 10:25:06 AM
#37557   Where in the heck is that update? bucks2pennies 09/14/15 08:23:53 PM
#37556   $RGBP and $BMSN will make nice moves based Kbro13 09/11/15 09:03:24 PM
#37555   If this was trading in the trips it Brakeman 09/11/15 07:54:13 PM
#37554   Why Kbro13 explain please oneflew12 09/11/15 07:29:20 PM